Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410438 | 0.84 | TTR (0.41) | TTRALBALDH1A1CYP2A6EGLN2 | |
| SCHEMBL23099521 | 0.78 | TTR (0.52) | TTRALBEGLN2MEN1KMT2A | |
| SCHEMBL27254466 | 0.78 | TTR (0.58) | TTRALBALDH1A1CYP2A6EGLN2 | |
| SCHEMBL8036320 | 0.78 | EGLN2 (0.40) | TTRALBALDH1A1CYP2A6EGLN2 | |
| SCHEMBL11981507 | 0.77 | TRPV4 (0.38) | TTRALBALDH1A1CYP2A6EGLN2 | |
| SCHEMBL1312296 | 0.75 | TTR (0.72) | TTRALBEGLN2MEN1KMT2A | |
| SCHEMBL13641418 | 0.75 | EGLN2 (0.36) | TTRALBALDH1A1CYP2A6EGLN2 | |
| SCHEMBL1997670 | 0.75 | TTR (0.48) | TTRALBEGLN2MEN1KMT2A | |
| SCHEMBL10120483 | 0.75 | KCNJ6 (0.40) | TTRALBALDH1A1CYP2A6EGLN2 | |
| SCHEMBL15321453 | 0.75 | TTR (0.43) | TTRALBALDH1A1CYP2A6EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313556-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4514799-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MRJA Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119384421-A | Certain chemical entities, compositions and methods | 沐尔佳治疗公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2023212612-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN SHAWN (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212612-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN SHAWN (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-3174115-B1 | CHARGE TRANSPORT MATERIAL | NISSAN CHEMICAL CORP (JP) | 2020-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313556-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIT, PRKCH, PRKCB | TTR 4850/4885ALB 4672/4885ALDH1A1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.